DNLI — Denali Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1714899 ·
Last close
$25.68
Market Cap
$4.08B
52W High
$27.30
52W Low
$17.71
ADV30
1,880,401
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -137,357,000 | -128,447,000 | 1,266,023,000 | 387,626,000 | 339,925,000 |
| Dec 2025 | 0 | — | -137,365,000 | -128,549,000 | 1,144,854,000 | 205,326,000 | 131,093,000 |
| Sep 2025 | 0 | — | -137,434,000 | -126,902,000 | 1,055,621,000 | 90,963,000 | 129,424,000 |
| Jun 2025 | 0 | — | -134,963,000 | -124,119,000 | 1,166,241,000 | 141,207,000 | 139,188,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-412,600,000
Investing CF
$255,281,000
Financing CF
$189,216,000
CapEx
$-15,972,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.97
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,051,524,000
Inventory
—
Receivables
$2,177,000
ST Investments
$662,553,000
EBIT TTM
$-555,342,000
Pretax Income TTM
$-512,438,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -555,342,000 | -512,540,000 | 1,144,854,000 | 131,093,000 | — | -412,600,000 |
| Dec 2024 | 0 | -501,878,000 | -422,773,000 | 1,374,180,000 | 144,496,000 | — | -347,694,000 |
| Dec 2023 | 330,531,000 | -196,699,000 | -145,224,000 | 1,153,917,000 | 122,963,000 | — | -357,991,000 |
| Dec 2022 | 108,463,000 | -340,744,000 | -325,991,000 | 1,460,242,000 | 417,812,000 | — | -244,716,000 |
TTM Snapshot
Revenues TTM
$10,111,000
NetIncome TTM
$-394,432,000
OpCashFlow TTM
$0
Assets (Latest)
$1,374,180,000
Forward EPS
$-2.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | $4.36B | $20.00 | — |
| ADPT | Adaptive Biotechnologies Corp | $3.37B | $21.06 | — |
| BEAM | Beam Therapeutics Inc. | $3.36B | $32.68 | — |
| CRSP | CRISPR Therapeutics AG | $5.25B | $53.35 | — |
| TWST | Twist Bioscience Corp | $5.64B | $90.64 | — |
News headlines (Yahoo Finance, 1h cache)
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barr
2026-07-09 20:01 · Yahoo
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
2026-06-23 14:46 · Yahoo
Denali to Sell Priority Review Voucher for $195M Cash Boost
2026-06-19 12:40 · Yahoo
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
2026-06-18 12:00 · Yahoo
Pfizer CFO to step down; Denali sells a regulatory fast-pass
2026-06-18 10:55 · Yahoo
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease
2026-06-16 22:18 · Yahoo
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
2026-06-11 10:20 · Yahoo
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline
2026-06-02 10:07 · Yahoo
Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos
2026-06-01 17:12 · Yahoo
Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says
2026-05-26 15:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.